𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Open-label surgical trials for Parkinson disease: Time for reconsideration

✍ Scribed by Ron L. Alterman; Michele Tagliati; C. Warren Olanow

Book ID
101467632
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
74 KB
Volume
70
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Interpreting the results of Parkinson's
Interpreting the results of Parkinson's disease clinical trials: Time for a change
✍ Nick H. G. Holford; John G. Nutt πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 199 KB πŸ‘ 1 views

## Abstract Randomized clinical trials testing putative disease‐modifying agents in Parkinson's disease (PD) have yielded controversial results that have not influenced evidence‐based recommendations for the treatment of PD. We argue that the failure of these clinical trials may be linked to end po

Atomoxetine for the treatment of executi
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 321 KB πŸ‘ 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi